MetaVia Inc.
A clinical-stage biotech company developing drugs for cardiometabolic diseases.
MTVA | US
Overview
Corporate Details
- ISIN(s):
- US64132R1077
- LEI:
- Country:
- United States of America
- Address:
- 545 CONCORD AVENUE, 2138 CAMBRIDGE
- Website:
- https://metaviatx.com/
- Sector:
- Manufacturing
Description
MetaVia Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals for cardiometabolic diseases. The company's pipeline is centered on innovative treatments for obesity and metabolic dysfunction-associated steatohepatitis (MASH). Its lead product candidate, DA-1726, is a dual oxyntomodulin (OXM) analog agonist that functions on both the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR), under development for obesity. Another key asset is Vanoglipel, a G-Protein-Coupled Receptor 119 (GPR119) agonist being developed for MASH.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all MetaVia Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for MetaVia Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for MetaVia Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
